Analysts Set Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Price Target at $62.17

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have been given an average rating of “Hold” by the seven research firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $62.1667.

A number of research firms have recently weighed in on SUPN. Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Finally, Zacks Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th.

Supernus Pharmaceuticals Trading Up 0.2%

Shares of Supernus Pharmaceuticals stock opened at $50.39 on Tuesday. The company’s fifty day simple moving average is $51.35 and its two-hundred day simple moving average is $49.87. The company has a market cap of $2.90 billion, a P/E ratio of -74.10, a PEG ratio of 1.56 and a beta of 0.73. Supernus Pharmaceuticals has a 12-month low of $29.16 and a 12-month high of $59.68.

Insider Transactions at Supernus Pharmaceuticals

In other news, CEO Jack A. Khattar sold 35,000 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $50.37, for a total value of $1,762,950.00. Following the sale, the chief executive officer directly owned 958,100 shares of the company’s stock, valued at $48,259,497. This represents a 3.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Frederick M. Hudson sold 5,369 shares of the company’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $50.61, for a total transaction of $271,725.09. Following the completion of the sale, the director directly owned 60,413 shares in the company, valued at $3,057,501.93. This represents a 8.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 120,881 shares of company stock worth $6,139,356. 8.80% of the stock is owned by insiders.

Institutional Trading of Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Hantz Financial Services Inc. lifted its stake in Supernus Pharmaceuticals by 81.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 281 shares during the period. Rockefeller Capital Management L.P. lifted its stake in Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 660 shares during the period. Torren Management LLC bought a new position in Supernus Pharmaceuticals during the 4th quarter valued at about $49,000. USA Financial Formulas bought a new position in Supernus Pharmaceuticals during the 3rd quarter valued at about $50,000. Finally, EverSource Wealth Advisors LLC bought a new position in Supernus Pharmaceuticals during the 2nd quarter valued at about $51,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.